Type 5 Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction and Cardiovascular Disease

2007 ◽  
Vol 15 (2) ◽  
pp. 76-86 ◽  
Author(s):  
Gautham Ravipati ◽  
John A. McClung ◽  
Wilbert S. Aronow ◽  
Stephen J. Peterson ◽  
William H. Frishman
Keyword(s):  
Cardiovascular Disease ◽  
Erectile Dysfunction ◽  
Phosphodiesterase Inhibitors ◽  
Type 5 Phosphodiesterase Inhibitors

scholarly journals Approaches to the rational choice of type 5 phosphodiesterase inhibitors in patients presenting with cardiovascular and endocrine diseases

2010 ◽  
Vol 56 (6) ◽  
pp. 63-72
Author(s):  
V V Rafal'skiĭ ◽  
A N Baglikov
Keyword(s):  
Erectile Dysfunction ◽  
Side Effects ◽  
Rational Choice ◽  
Therapeutic Option ◽  
Phosphodiesterase Inhibitors ◽  
Pharmaceutical Products ◽  
Efficacy And Safety ◽  
Adverse Side Effects ◽  
Endocrine Diseases ◽  
Type 5 Phosphodiesterase Inhibitors

After the advent of four type 5 phosphodiesterase inhibitors (PDEI 5), viz. sildenafil, tadalafil, vardenafil, and udenafil, designed for the treatment of erectile dysfunction both physicians and patients found themselves faced with the problem of choosing an optimal therapeutic option. This paper contains comparative data on the efficacy and safety of different PDEI 5. The approaches to the rational choice of these preparations for the treatment of patients presenting with cardiovascular and endocrine diseases are discussed. Comparative controlled clinical studies failed to yield definitive information about advantages of one or another agent representing this group of pharmaceutical products. Nevertheless, the currently available data permit to draw the conclusion that the use of vardenafil and tadalafil ensures better compliance of patients with the prescribed therapy. Certain authors advocate the desirability of vardenafil application to the treatment of patients presenting with a background pathology. It is emphasized that all available PDEI 5 have a beneficial safety profile, with wardenafil being virtually free from adverse side effects.

scholarly journals ERECTILE DYSFUNCTION AND ITS PHARMACOLOGY: AN OVERVIEW

2017 ◽  
Vol 10 (2) ◽  
pp. 17 ◽  
Author(s):  
Sunil Kumar Patnaik ◽  
Haritha Polimati ◽  
Rajeswara Rao Pragada
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Erectile Dysfunction ◽  
Cigarette Smoking ◽  
Penile Erection ◽  
Treatment Strategies ◽  
Phosphodiesterase Inhibitors ◽  
Current Treatment ◽  
Complex Nature ◽  
Factors Associated

It has been estimated that currently over 150 million men worldwide suffer from erectile dysfunction (ED) and by 2025, the figure will increase beyond 322 millions. ED is the inability to achieve, and/or maintain penile erection sufficient for satisfactory sexual intercourse, and was previously regarded as the part of aging. It is associated with certain diseases and life style habits with a cause-effect relationship, including diabetes mellitus, hypertension, dyslipidemia, and cigarette smoking. Internationally, most of the men with ED fail to pursue treatment due to the complex nature of sexuality, taboos, cultural restrictions, and acceptance of ED as a normal sequel of aging. In this review, we discussed the physiology, diagnosis, and risk factors associated with ED and current treatment strategies for ED.Keywords: Erectile dysfunction, Diabetes, Penile erection, Phosphodiesterase inhibitors.

Erectile Dysfunction in the Patients with Cardiovascular Disease

2006 ◽  
Vol 47 (3) ◽  
pp. 279 ◽  
Author(s):  
Hyun Woo Kim ◽  
Wang Jin Park ◽  
Su Yeon Cho
Keyword(s):  
Cardiovascular Disease ◽  
Erectile Dysfunction

scholarly journals Low intensity Extra Corporeal Shock Wave Therapy in Patients with Erectile Dysfunction: Our experience in ACKU

2020 ◽  
Vol 23 (2) ◽  
pp. 176-180
Author(s):  
Md Fazal Naser ◽  
Mahmood Hasan ◽  
Md Waliul Islam ◽  
Tajkera Sultana Chowdhury ◽  
Md Shohrab Hossain
Keyword(s):  
Erectile Dysfunction ◽  
Erectile Function ◽  
Treatment Protocol ◽  
Phosphodiesterase Inhibitors ◽  
Shockwave Therapy ◽  
Low Intensity ◽  
Weekly Session ◽  
Linear Probe ◽  
Study Population ◽  
Energy Flux Density

Introduction: Oral 5-phosphodiesterase inhibitors (PDE5-I) is the main therapeutical options in erectile dysfunction (ED). It shows good results, but non-responders lack other effective options and its effect is also not long lasting. Since last few years, low-intensity extracorporeal shockwave therapy (Li-ESWT) in the corpora cavernosa showing promising results. This article presents our early experiences in Advanced Center of Kidney disease and Urology (ACKU) with the aim to evaluate clinical efficacy of Li-ESWT. Materials and methods: Thirty four patients with ED were prospectively included in the study during the period of January 2018 to Jun 2019.Treatment was performed using the PiezoWave2 (Richard Wolf, Germany) device with a linear probe. Treatment protocol included a weekly session for four weeks. Each session delivered 2000 shocks on the perineum plus 4000 shocks on dorsum penis with an energy flux density (EFD) of 0.160 mJ/mm2. Every patient has been re-evaluated 1.5 and 3 months after the last session. Pre- and post-procedure International Index Erectile Function – Erectile function domain (IIEF-EF) score, Erection Hardness Score (EHS) and Global Assessment Questionnaire-Question 1 (GAQ-Q1) answers were obtained. Results: Mean age of the study population was 39.4 (±12.9) years, 35.29% diabetic, 20.59% with hypertension and 55.85% smokers. Mean baseline IIEF-EF was 14.6, at 6 week post LiSWT was 16.4 (p >0.05) and at 3 months post LiSWT was 19.2 (p < 0.05). EHS was significantly improved at 3 month in comparison to baseline (p<0.05). 20.59% patients answered positively to GAQ-Q1 at 6 week and 61.76% at 3 months. IIEF-EF score change of >5 and increase of EHS >2 were observed in 62.88% and 70.59% study subjects respectively. Conclusions: Li-ESWT is a safe, harmless and repeatable treatment tool for ED with good outcomes reported. Bangladesh Journal of Urology, Vol. 23, No. 2, July 2020 p.176-180

scholarly journals Disfungsi ereksi pada penyakit kardiovaskular

2016 ◽  
Vol 8 (1) ◽  
Author(s):  
Nancy Sasube ◽  
Starry H. Rampengan
Keyword(s):  
Quality Of Life ◽  
Cardiovascular Disease ◽  
Erectile Dysfunction ◽  
Sexual Function ◽  
Risk Mitigation ◽  
Time Frame ◽  
Lifestyle Changes ◽  
Cvd Risk ◽  
Adherence To Medication

Abstract: Erectile dysfunction (ED) is common among cardiovascular disease (CVD) patients. It is an important component of the quality of life. Moreover, it also confers an independent risk for future CV events. There is usual a 3-year time frame between the onset of ED symptoms and a CV event which offers an opportunity for risk mitigation. Thus, sexual function should be incorporated into CVD risk assessment for all males. Algorithms for the management of patient with ED have been proposed according to the risk for sexual activity and future (comprising of both lifestyle changes and pharmacological treatment) improve overall vascular health, including sexual function. Proper sexual counselling improves the quality of life and increase adherence to medication. Testosterone assessment may be useful for both diagnosis of ED, risk stratification, and further management. There are issues to be addressed, such as whether PDE5 inhibitors reduce CV risk. Management of ED requires a collaborative approach and the role of the cardiologist is pivotal.Keywords: cardiovascular disease, erectile dysfunction, sexual functionAbstrak: Disfungsi ereksi (DE) umumnya ditemukan pada pasien dengan penyakit kardiovaskular. DE merupakan komponen penting terhadap penurunan kualitas hidup pada laki-laki dan merupakan indikator terhadap risiko kejadian penyakit kardiovaskular di masa depan. Terdapat jangka waktu sekitar 3 tahun antara munculnya DE dan kejadian penyakit kardiovaskular, sehingga masih ada kesempatan untuk mencegah risiko yang akan terjadi. Dengan demikian fungsi seksual harus dimasukkan dalam penilaian risiko penyakit kardiovaskular pada semua laki-laki. Algoritma untuk penanganan pasien DE telah dirumuskan sesuai dengan risiko aktivitas seksual dan kejadian penyakit kardiovaskular di masa depan. Beberapa pendekatan untuk mengurangi resiko penyakit kardiovaskular terdiri dari perubahan gaya hidup dan pengobatan farmakologi dapat meningkatkan kesehatan termasuk fungsi seksual. Konseling seksual yang tepat dapat meningkatkan kualitas hidup dan meningkatkan kepatuhan terhadap pengobatan. Penggunaan testosteron dan inhibitor PDE5 dapat bermanfaat dalam pengobatan DE. Penanganan DE memerlukan kerjasama dari berbagai bidang spesialistik termasuk peran dari kardiologis.Kata kunci: disfungsi ereksi, fungsi seksual, penyakit kardiovaskular

Sign in / Sign up

Export Citation Format

Share Document